BeyondSpring, Inc.

BYSI | $1.81 -2.16% -2.21% 56K

(0.0% 1d) (-40.2% 1m) (66.7% 1y) (0.0% 2d) (0.0% 3d) (-13.9% 7d) (-50.12% volume)
Earnings Calendar: 2022-06-15
Market Cap: $ 70,452,597
http://www.beyondspringpharma.com
Sec Filling | Patents | 61 employees

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab for the treatment of NSCLC; and programmed cell death protein 1 and CTLA-4 antibodies to treat small cell lung cancer. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the University of Washington and the Fred Hutchinson Cancer Research Center. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

cancer lung cancer antibody t-cell lungs clinical trials treatment ceiling

add to watch list Paper trade email alert is off

Press-releases

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| -42.31% | O: 0.0% H: 12.18% C: 11.22%
first lung cancer study

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 65.14% | O: -1.83% H: 12.15% C: 11.21%
nasdaq

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
Published: 2024-01-10 (Crawled : 20:00) - beyondspringpharma.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 99.98% | O: 1.1% H: 2.18% C: -6.57%
nasdaq

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Published: 2023-12-18 (Crawled : 22:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 78.22% | O: -6.93% H: 9.57% C: 1.06%
nasdaq

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
Published: 2023-11-07 (Crawled : 12:00) - beyondspringpharma.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 85.01% | O: -5.43% H: 7.6% C: 4.03%
plinabulin tumors cell preclinical immunotherapy poc

BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 32.07% | O: -0.03% H: 0.0% C: 0.0%
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 73.08% | O: -6.73% H: 12.37% C: 2.06%
glioblastoma

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 69.81% | O: 0.94% H: 0.47% C: -2.8%
nasdaq

SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M

Health Technology

| 28.02% | O: -1.68% H: 0.0% C: 0.0%
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 60.71% | O: 0.0% H: 7.14% C: -5.36%
candidate symposium cancer protein therapeutics molecular

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
Published: 2023-10-23 (Crawled : 12:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 80.0% | O: 2.0% H: 7.84% C: 1.96%

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Published: 2023-10-04 (Crawled : 20:00) - globenewswire.com
BYSI | $1.81 -2.16% -2.21% 56K

Health Technology

| 137.78% | O: -4.89% H: 9.61% C: 7.89%
nasdaq

See all